A Cuello

Summary

Affiliation: McGill University
Country: Canada

Publications

  1. Cuello A, Bruno M, Allard S, Leon W, Iulita M. Cholinergic involvement in Alzheimer's disease. A link with NGF maturation and degradation. J Mol Neurosci. 2010;40:230-5 pubmed publisher
  2. Malcolm J, Breuillaud L, Do Carmo S, Hall H, Welikovitch L, Macdonald J, et al. Neuropathological changes and cognitive deficits in rats transgenic for human mutant tau recapitulate human tauopathy. Neurobiol Dis. 2019;127:323-338 pubmed publisher
    ..These results support the concept that progressive tauopathy correlates with brain atrophy and cognitive impairment. ..
  3. Foret M, Do Carmo S, Lincoln R, Greene L, Zhang W, Cuello A, et al. Effect of antioxidant supplements on lipid peroxidation levels in primary cortical neuron cultures. Free Radic Biol Med. 2019;130:471-477 pubmed publisher
    ..Overall these results provide the necessary foundation and impetus towards using H4BPMHC for elucidating and mapping lipid peroxyl radical contributions to ROS-associated pathological processes in neurons. ..
  4. Welikovitch L, Do Carmo S, Maglóczky Z, Szocsics P, Lőke J, Freund T, et al. Evidence of intraneuronal Aβ accumulation preceding tau pathology in the entorhinal cortex. Acta Neuropathol. 2018;136:901-917 pubmed publisher
    ..Together, these findings indicate that the lifelong accrual of intraneuronal Aβ may be a potential trigger for downstream AD-related pathogenic events in early disease stages. ..
  5. Do Carmo S, Cuello A. Modeling Alzheimer's disease in transgenic rats. Mol Neurodegener. 2013;8:37 pubmed publisher
    ..Consequently, rat models of AD should allow a more sophisticated and accurate assessment of the impact of pathology and novel therapeutics on cognitive outcomes. ..
  6. Allard S, Jacobs M, Do Carmo S, Cuello A. Compromise of cortical proNGF maturation causes selective retrograde atrophy in cholinergic nucleus basalis neurons. Neurobiol Aging. 2018;67:10-20 pubmed publisher
    ..This study demonstrates that impairments in the extracellular maturation of proNGF are sufficient to cause a somatodendritic retrograde degeneration of the BFCNs. ..
  7. request reprint
    Iulita M, Cuello A. The NGF Metabolic Pathway in the CNS and its Dysregulation in Down Syndrome and Alzheimer's Disease. Curr Alzheimer Res. 2016;13:53-67 pubmed
    ..This chapter will discuss the physiological role of NGF and its biological significance to cholinergic neurons of the CNS, and present the evidence for a dysregulation of the NGF metabolism in Alzheimer's disease and Down syndrome. ..
  8. request reprint
    Cuello A, Bruno M. The failure in NGF maturation and its increased degradation as the probable cause for the vulnerability of cholinergic neurons in Alzheimer's disease. Neurochem Res. 2007;32:1041-5 pubmed
    ..This metabolic scenario in Alzheimer's disease should result in the failure of NGF trophic support to forebrain cholinergic neurons and thus explaining the vulnerability of these neurons in this neurodegenerative condition. ..
  9. Do Carmo S, Crynen G, Paradis T, Reed J, Iulita M, Ducatenzeiler A, et al. Hippocampal Proteomic Analysis Reveals Distinct Pathway Deregulation Profiles at Early and Late Stages in a Rat Model of Alzheimer's-Like Amyloid Pathology. Mol Neurobiol. 2018;55:3451-3476 pubmed publisher
    ..These results shed new light on the molecular pathways affected by the early accumulation of Aβ and how the evolving amyloid pathology impacts other complex metabolic pathways. ..

More Information

Publications18

  1. Hall H, Iulita M, Gubert P, Flores Aguilar L, Ducatenzeiler A, Fisher A, et al. AF710B, an M1/sigma-1 receptor agonist with long-lasting disease-modifying properties in a transgenic rat model of Alzheimer's disease. Alzheimers Dement. 2018;14:811-823 pubmed publisher
    ..With M1/sigma-1 activity and long-lasting disease-modifying properties at low dose, AF710B is a promising novel therapeutic agent for treating Alzheimer's disease. ..
  2. Iulita M, Allard S, Richter L, Munter L, Ducatenzeiler A, Weise C, et al. Intracellular A? pathology and early cognitive impairments in a transgenic rat overexpressing human amyloid precursor protein: a multidimensional study. Acta Neuropathol Commun. 2014;2:61 pubmed publisher
  3. request reprint
    Iulita M, Caraci F, Cuello A. A Link Between Nerve Growth Factor Metabolic Deregulation and Amyloid-?-Driven Inflammation in Down Syndrome. CNS Neurol Disord Drug Targets. 2016;15:434-47 pubmed
    ..It further considers the potential of the NGF metabolic pathway as a new pharmacological target to slow down the neurodegenerative process both in Alzheimer's disease and in individuals with Down syndrome. ..
  4. Iulita M, Ower A, Barone C, Pentz R, Gubert P, Romano C, et al. An inflammatory and trophic disconnect biomarker profile revealed in Down syndrome plasma: Relation to cognitive decline and longitudinal evaluation. Alzheimers Dement. 2016;12:1132-1148 pubmed publisher
    ..Our findings support the combination of plasma and cognitive assessments for the identification of DS individuals at risk of dementia. ..
  5. Caraci F, Iulita M, Pentz R, Flores Aguilar L, Orciani C, Barone C, et al. Searching for new pharmacological targets for the treatment of Alzheimer's disease in Down syndrome. Eur J Pharmacol. 2017;817:7-19 pubmed publisher
    ..We further examine the relevance of newly discovered biological markers for earlier dementia diagnosis in this population. ..
  6. Iulita M, Bistué Millón M, Pentz R, Aguilar L, Do Carmo S, Allard S, et al. Differential deregulation of NGF and BDNF neurotrophins in a transgenic rat model of Alzheimer's disease. Neurobiol Dis. 2017;108:307-323 pubmed publisher
  7. Cuello A. Early and Late CNS Inflammation in Alzheimer's Disease: Two Extremes of a Continuum?. Trends Pharmacol Sci. 2017;38:956-966 pubmed publisher
    ..This early CNS inflammation should be considered a promising therapeutic target as we continue searching for an unequivocal diagnosis of AD preclinical stages. ..
  8. Cuello A, Allard S, Ferretti M. Evidence for the accumulation of Abeta immunoreactive material in the human brain and in transgenic animal models. Life Sci. 2012;91:1141-7 pubmed publisher
    ..Finally, we discuss the possible pathological significance of these intracellular APP fragments and the expected future research directions regarding this thought-provoking problem. ..
  9. Cuello A, Canneva F. Impact of intracellular beta-amyloid in transgenic animals and cell models. Neurodegener Dis. 2008;5:146-8 pubmed publisher
    ..Moreover, intracellular pathology would be independent and additive to the toxic effects of the extracellular Abeta burden...